Today, iNtRON Biotechnology (“iNtRON,” www.intodeworld.com) stated that it had developed the 2nd generation of robotic bacteriophage technology.

In addition to the previously reported customised CRISPR/Cas system for the advancement of bacteriophage engineering, random transposon mutagenesis technology may now be deployed into the bacteriophage genome. By virtue of the advancement, non-essential genes in the bacteriophage genome can be found, and a gene transfer for adding new functions to the target site in addition to genome size control can be carried out much more readily.
In addition to using bacteriophages based on PHAGERUS® to kill viruses, iNtRON aims to use the PHAGERIA® and PHAGERIARUS® platform technologies to create immunotherapeutic drugs. For the Company to be able to freely create and produce the bacteriophage genome as wanted, it is necessary to acquire more advanced Robot Bacteriophage technology.

Source: Prnewswire